Pre-HSCT serum angiopoietin-2 levels in patients and healthy controls, ng/mL
| Diagnosis . | No. . | Mean . | SD . | Median . | Range . |
|---|---|---|---|---|---|
| De novo AML | 39 | 4.00 | 7.30 | 2.34 | 0.46-46.42 |
| AML secondary to MDS | 30 | 2.48 | 1.57 | 2.01 | 0.77-6.56 |
| AML secondary to other malignancies | 10 | 7.43 | 14.66 | 3.28 | 0.18-48.84 |
| MDS | 8 | 2.08 | 1.12 | 1.93 | 0.53-3.76 |
| MDS secondary to other malignancies | 3 | 3.97 | 1.31 | 4.17 | 2.57-5.17 |
| Sum of all myeloid malignancies* | 90 | 2.70 | 1.85 | 2.21 | 0.18-48.84 |
| Healthy controls | 20 | 1.17 | 1.00 | 0.87 | 0.27-4.51 |
| Diagnosis . | No. . | Mean . | SD . | Median . | Range . |
|---|---|---|---|---|---|
| De novo AML | 39 | 4.00 | 7.30 | 2.34 | 0.46-46.42 |
| AML secondary to MDS | 30 | 2.48 | 1.57 | 2.01 | 0.77-6.56 |
| AML secondary to other malignancies | 10 | 7.43 | 14.66 | 3.28 | 0.18-48.84 |
| MDS | 8 | 2.08 | 1.12 | 1.93 | 0.53-3.76 |
| MDS secondary to other malignancies | 3 | 3.97 | 1.31 | 4.17 | 2.57-5.17 |
| Sum of all myeloid malignancies* | 90 | 2.70 | 1.85 | 2.21 | 0.18-48.84 |
| Healthy controls | 20 | 1.17 | 1.00 | 0.87 | 0.27-4.51 |
AML indicates acute myeloid leukemia; and MDS, myelodysplastic syndrome.
Circulating Ang-2 serum levels were significantly elevated in patients compared with healthy controls (P < .001).